December 12, 2006 — Health Canada has approved a pen-like device for administering adalimumab in the treatment of moderate to severe rheumatoid arthritis and psoriatic arthritis; the European ...
The US Food and Drug Administration (FDA) has approved the biosimilar adalimumab-aaty (Yuflyma) in a citrate-free, high-concentration formulation, the manufacturer, Celltrion USA, announced today. It ...
On May 22, 2023, Boehringer Ingelheim announced that the FDA has approved the Cyltezo Pen, a new autoinjector option for Cyltezo (adalimumab-adbm). According to a previous announcement from Boehringer ...
The FDA previously approved YUFLYMA as a biosimilar to Humira ® for a variety of indications, including rheumatoid arthritis (RA), psoriatic arthritis (PsA), juvenile idiopathic arthritis (JIA), ...
Samsung Bioepis Co., Ltd. and Organon & Co. (NYSE: OGN) today announced that the US Food and Drug Administration (FDA) has designated the HADLIMA™ (adalimumab-bwwd) high- and low-concentration (40 ...
Please provide your email address to receive an email when new articles are posted on . Humira biosimilar Amjevita can cost $1,558 for commercial plans, a discount of 14% compared with Humira’s 2020 ...
Research presented at EULAR 2022 demonstrated the pharmacokinetic equivalence of a low-concentration version of the adalimumab biosimilar SB5 and a high-concentration version. While 2023 is becoming ...
Please provide your email address to receive an email when new articles are posted on . Upadacitnib is equivalent or superior to adalimumab in improving patient reported outcomes among those with RA ...
The PTAB has denied institution of inter partes review of two Abbvie patents that relate to HUMIRA (adalimumab). On February 9, 2018, the PTAB denied Sandoz’s IPR2017-01824 on U.S. Patent No.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback